Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuqing Lou

Showing results (51-60 of 115) with videos related to

Pageof 12
Sort By:
Medical Oncology (Northwood, London, England)|May 14, 2015
Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patientsShaohua Cui, Yizhuo Zhao, Aiqin Gu, et al.
Frontiers in Pharmacology|December 16, 2022
LncRNA MEG3: Potential stock for precision treatment of cardiovascular diseasesZining Li, Jialiang Gao, Di Sun, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|January 14, 2011
α-adducin Gly460Trp polymorphism and essential hypertension risk in Chinese: a meta-analysisKuo Liu, Ya Liu, Jielin Liu, et al.
International Journal of Nanomedicine|January 20, 2023
Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle DeliveryJun Lu, Yuqing Lou, Yanwei Zhang, et al.
Oncotarget|November 5, 2016
MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinomaYanwei Zhang, Keke Yu, Song Hu, et al.
Scientific Reports|November 5, 2016
EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutationJianlin Xu, Haitang Yang, Bo Jin, et al.
Targeted Oncology|March 15, 2020
Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro StudyYuqing Lou, Jianlin Xu, Yanwei Zhang, et al.
Cell Death & Disease|February 11, 2021
Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesisYuqing Lou, Jianlin Xu, Yanwei Zhang, et al.
Frontiers in Oncology|July 28, 2020
CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma PatientsYanwei Zhang, Beibei Sun, Minjuan Hu, et al.
Cancer Letters|September 20, 2025
Hinokitiol preferentially suppresses metastatic lung adenocarcinoma via TMDD1-mediated ferroptosis induction and iron-sulfur cluster inhibitionYanbin Kuang, Suyang Yang, Xiaoting Tian, et al.
Pageof 12

Showing results (51-60 of 115) with videos related to

Sort By:
Pageof 12
Medical Oncology (Northwood, London, England)|May 14, 2015
Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patientsShaohua Cui, Yizhuo Zhao, Aiqin Gu, et al.
Frontiers in Pharmacology|December 16, 2022
LncRNA MEG3: Potential stock for precision treatment of cardiovascular diseasesZining Li, Jialiang Gao, Di Sun, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|January 14, 2011
α-adducin Gly460Trp polymorphism and essential hypertension risk in Chinese: a meta-analysisKuo Liu, Ya Liu, Jielin Liu, et al.
International Journal of Nanomedicine|January 20, 2023
Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle DeliveryJun Lu, Yuqing Lou, Yanwei Zhang, et al.
Oncotarget|November 5, 2016
MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinomaYanwei Zhang, Keke Yu, Song Hu, et al.
Scientific Reports|November 5, 2016
EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutationJianlin Xu, Haitang Yang, Bo Jin, et al.
Targeted Oncology|March 15, 2020
Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro StudyYuqing Lou, Jianlin Xu, Yanwei Zhang, et al.
Cell Death & Disease|February 11, 2021
Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesisYuqing Lou, Jianlin Xu, Yanwei Zhang, et al.
Frontiers in Oncology|July 28, 2020
CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma PatientsYanwei Zhang, Beibei Sun, Minjuan Hu, et al.
Cancer Letters|September 20, 2025
Hinokitiol preferentially suppresses metastatic lung adenocarcinoma via TMDD1-mediated ferroptosis induction and iron-sulfur cluster inhibitionYanbin Kuang, Suyang Yang, Xiaoting Tian, et al.
Pageof 12